• Benitec highlighted durable clinical responses to investigational gene therapy BB-301 in oculopharyngeal muscular dystrophy patients with dysphagia, citing follow-up at 12 months and 24 months in low-dose Cohort 1.
• All Cohort 1 study completers met company-defined responder criteria at 12 months in Phase 1b/2a open-label dose-escalation study.
• Interim data from first patient in higher-dose Cohort 2 at 3 months indicated responder status, with improved depth of response versus Cohort 1 in a preliminary comparison.
• Program update reiterated no treatment-related severe adverse events reported to date, with FDA Fast Track designation and Orphan Drug designation from FDA and EMA.
• Benitec positioned BB-301 as only clinical-stage therapy in development designed to treat OPMD-related dysphagia, targeting roughly 15,000 patients across North America, Europe, and Israel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief on May 16, 2026, and is solely responsible for the information contained therein.